SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the Date October 10, 2001
CeNeS Pharmaceuticals plc
--------------------------------------------------------------------------------
(Translation of registrant's name into English)
COMPASS HOUSE
VISION PARK
CHIVERS WAY
HISTON
CAMBRIDGE CB4 9ZR
UNITED KINGDOM
--------------------------------------------------------------------------------
(Address of principal executive office)
(Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F.)
Form 20-F |X| Form 40-F |_|
(Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.)
Yes |_| No |X|
34427.0001
CeNeS Pharmaceuticals PLC
9 October 2001
CENES PHARMACEUTICALS PLC ("CeNeS " or "the Company")
Re Directorate
The board of CeNeS yesterday accepted the resignations of Dr Daniel Roach, the
Company's chief executive officer, and Mr Martyn Collett, the Company's
commercial director, with immediate effect as proposed in the Company's interim
results announcement released on 1 October 2001.
9 October 2001
* * * * *
2
CeNeS Pharmaceuticals PLC
9 October 2001
CENES PHARMACEUTICALS PLC (the "Company")
Director(s) Shareholding
The Company was today informed that the following directors of the Company
purchased a total of 499,999 ordinary shares of 10p each in the Company
("Ordinary Shares") on 5th October 2001, and a total of 2,293,887 Ordinary
Shares on 8th October 2001. These purchases have been split as follows:
Director/ Date(s) of Number of Ordinary Purchase price per % interest following Number interest
Shareholder purchase Shares purchased Ordinary Share (p) purchase(s) following purchase(s)
----------- -------- ---------------- ------------------ ----------- ---------------------
A.G. Goodman 5 Oct 2001 166,666 10 1/4 5.32 8,551,471*
8 Oct 2001 729,562 9 1/2
Dr D. J. Roach 5 Oct 2001 166,666 10 1/4 5.32 8,551,471*
8 Oct 2001 729,562 9 1/2
N. R. Clark 8 Oct 2001 52,600 9 1/2 0.03 52,600
M. Collett 8 Oct 2001 52,600 9 1/2 0.04 56,661
ATM 5 Oct 2001 166,667 10 1/4 4.77 7,655,243*
8 Oct 2001 729,563 9 1/2
Note:
* 7,655,243 of these Ordinary Shares are held by ATM Global Investments Limited
("ATM"), a company controlled by A.G. Goodman and Dr D. J. Roach.
9 October 2001
* * * * *
3
CeNeS Pharmaceuticals PLC
9 October 2001
TO: CITY EDITORS 9th October, 2001
FOR IMMEDIATE RELEASE
CeNeS Pharmaceuticals PLC
Additional Listing
Application has today been made to the UK Listing Authority for the admission to
the Official List and to the London Stock Exchange for the admission to trading
of 9,149,885 Ordinary Shares of 10 pence each in the capital of CeNeS
Pharmaceuticals Plc ("CeNeS").
As announced with the interim results released on 1 October 2001, the shares
have been subscribed for by Elan Corporation ("Elan"), at a price of 16.5 pence
per share, in connection with an extension to the scope of the M6G/Medipad
business venture agreement between CeNeS and Elan, whereby additional rights to
M6G have been assigned by CeNeS to the business venture. The Shares will rank
pari passu in all respects with the existing Ordinary Shares of 10 pence each.
* * * * *
4
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
CENES PHARMACEUTICALS PLC
Date: October 10, 2001 By: /s/ Neil Clark
------------------------------------
Name: Neil Clark
Title: Chief Operating Office and
Finance Director
5